Stockreport

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% [Yahoo! Finance]

Novartis AG  (NVS) 
Last novartis ag earnings: 4/28 01:00 am Check Earnings Report
US:NYSE Investor Relations: novartis.com/investors
PDF 40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years Fabhalta granted priority review by FDA for traditional approval B [Read more]